Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Elrexfio (elranatamab-bcmm)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Pfizer

Drug class:

CD3 agonist, BCMA inhibitor

Related drugs:

‹

blinatumomab (52)

epcoritamab-bysp (11)

tebentafusp-tebn (7)

tarlatamab-dlle (4)

mosunetuzumab-axgb (2)

talquetamab-tgvs (2)

teclistamab-cqyv (2)

glofitamab-gxbm (1)

odronextamab (1)

JNJ-63898081 (1)

ABBV-383 IV (0)

CD30 biAb-AATC (0)

JNJ-63709178 (0)

JNJ-67571244 (0)

PF-06671008 (0)

PF-07062119 (0)

PF-07260437 (0)

catumaxomab (0)

UMG2-CD3 BTCE (0)

Undisclosed HER2Bi-armed ATC (0)

activated CIK and bispecific antibody (0)

activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)

huCD33-BsAb (0)

›

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	elranatamab-bcmm Sensitive: A1 - Approval elranatamab-bcmm Sensitive : A1	elranatamab-bcmm Sensitive: A1 - Approval elranatamab-bcmm Sensitive : A1
IL6-L	Multiple Myeloma	IL6-L	Multiple Myeloma	elranatamab-bcmm Sensitive: C3 – Early Trials elranatamab-bcmm Sensitive : C3	elranatamab-bcmm Sensitive: C3 – Early Trials elranatamab-bcmm Sensitive : C3
TNFRSF17 amplification	Multiple Myeloma	TNFRSF17 amplification	Multiple Myeloma	elranatamab-bcmm Resistant: C3 – Early Trials elranatamab-bcmm Resistant : C3	elranatamab-bcmm Resistant: C3 – Early Trials elranatamab-bcmm Resistant : C3
CCL3-L	Multiple Myeloma	CCL3-L	Multiple Myeloma	elranatamab-bcmm Sensitive: C3 – Early Trials elranatamab-bcmm Sensitive : C3	elranatamab-bcmm Sensitive: C3 – Early Trials elranatamab-bcmm Sensitive : C3
IL17C-L	Multiple Myeloma	IL17C-L	Multiple Myeloma	elranatamab-bcmm Sensitive: C3 – Early Trials elranatamab-bcmm Sensitive : C3	elranatamab-bcmm Sensitive: C3 – Early Trials elranatamab-bcmm Sensitive : C3
Chr del(17p)	Multiple Myeloma	Chr del(17p)	Multiple Myeloma	elranatamab-bcmm Sensitive: C3 – Early Trials elranatamab-bcmm Sensitive : C3	elranatamab-bcmm Sensitive: C3 – Early Trials elranatamab-bcmm Sensitive : C3
Chr t(14;16)	Multiple Myeloma	Chr t(14;16)	Multiple Myeloma	elranatamab-bcmm Sensitive: C3 – Early Trials elranatamab-bcmm Sensitive : C3	elranatamab-bcmm Sensitive: C3 – Early Trials elranatamab-bcmm Sensitive : C3
Chr t(4;14)	Multiple Myeloma	Chr t(4;14)	Multiple Myeloma	elranatamab-bcmm Sensitive: C3 – Early Trials elranatamab-bcmm Sensitive : C3	elranatamab-bcmm Sensitive: C3 – Early Trials elranatamab-bcmm Sensitive : C3